Predict DILI with greater confidence
De-risk drug development with standardized 3D liver microtissues
Visit InSphero at the 56th Annual Meeting of the Society of Toxicology to learn how our standardized 3D liver microtissues can help you predict drug-induced liver injury (DILI) with high sensitivity, without sacrificing specificity. With PHH-derived liver microtissues in our new GravityTRAP™ 384 Microtissue Platform, and the launch of 3D Cynomolgus Monkey Liver Microtissues, you can now harness the full power of 3D liver spheroids from HTS to mechanistic and investigative tox studies. Hope to see you in Baltimore!
Sneak Peek: Achieve higher throughput and greater relevance with 384-well Human Liver Microtissues
HTS DILI prediction meets 3D PHH
What do HepG2, HepaRG, THLE, and iPSC-derived hepatocytes have in common? They are all cell types researchers use to try to replicate fully differentiated, functional primary human hepatocytes (PHH), but these cells all fall short in one or more ways. At ToxExpo 2017, we'll be previewing our new GravityTRAP™ 384 Microtissue Platform, which enables early-stage, short term DILI screening in a spheroid-optimized high-throughput format compatible with today's state-of-the-art liquid handling and high content imaging systems. You'll soon be able to harness the benefits of working in high throughput AND using a physiologically relevant PHH-derived DILI model.
3D InSight™ Monkey Liver Microtissues
In vitro cyno: monkey microtissues for mechanistic & investigative tox
Now you can translate and troubleshoot hepatotoxicity detected in in vivo cynomolgus monkey studies using an in vitro 3D monkey liver model. At ToxExpo 2017, we'll be launching our new 3D InSight™ Monkey Liver Microtissues. This organotypic co-culture of primary cynomolgus hepatocytes retains the advanced, integrated biology required for species-specific studies in investigative toxicology.
Your 3D InSight™ Conference Planner
March 12-16, 2017
Baltimore Convention Center, Baltimore, MD USA
Exhibitor Hosted Session
Wednesday, 3:00 - 4:00 PM, CC Room 338
Advanced 3D Liver and Pancreatic Islet Microtissues for Safety and Efficacy Assessments
3D liver and pancreatic islet microtissues for safety and efficacy testing will be presented, highlighting data from a 110 compound validation study for predictive DILI, and mechanistic assessments for investigative toxicology. Novel data on the use of 3D Islet Microtissues for diabetes research and pancreatic safety will also be discussed.
Presented by Dr. Simon Messner, InSphero AG
Recommended Workshop Presentation
Wednesday, 9:30 AM - 12:15 PM, Room 321
An Industry Perspective on New and Emerging In Vitro Models for Assessing Hepatotoxicity Risk in Drug Discovery
Final Presentation in Workshop Session: 3D Cell Platforms to Advance Toxicological Sciences
Presented by Dr. Will Proctor, Genentech, Inc.
Monday, March 13, 9:30 AM - 12:45 PM
1253/P413: Assessment of Mitochondrial Activity in 3D Human Liver Microtissues As a Tool for Mechanistic Investigations of Adverse Drug Effects
Presented with Agilent Technologies
Tuesday, March 14, 9:30 AM - 12:45 PM
1651/P103: Evaluation of Species-Specific Drug-Induced Liver Injury in 3D Rat, Dog, Monkey, and Human Liver Microtissues
Wednesday, March 15 1:15 PM - 4:30 PM
2763/P131: Establishment and Characterization of 3D Monkey Liver Microtissues for Species-Specific Toxicity Testing
Presented with Genentech